Myelitis due to enterovirus in patient on interferon therapy for chronic hepatitis B: case report.
Polidori
Marina
M
Tagliaferri
Enrico
E
Tascini
Carlo
C
Andreotti
Giovanni
G
Flammini
Sarah
S
Menichetti
Francesco
F
D000005:Abdomen / Q000473:pathology; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D004279:DNA, Viral / Q000134:cerebrospinal fluid; D004769:Enterovirus Infections / Q000097:blood / Q000134:cerebrospinal fluid / Q000150:complications* / Q000188:drug therapy; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D035002:Lower Extremity / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009187:Myelitis / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000821:virology*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins; D013116:Spinal Cord / Q000473:pathology; D016896:Treatment Outcome
D000998:Antiviral Agents; D004279:DNA, Viral; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a